Recursion Pharmaceuticals $500 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by Recursion Pharmaceuticals, Inc. of its Class A common stock for up to an aggregate amount of $500 million. The Class A common stock is listed on the Nasdaq Global Select Market under the symbol “RXRX.”
Recursion Pharmaceuticals is a clinical-stage biotechnology company industrializing drug discovery by decoding biology. Recursion is headquartered in Salt Lake City, Utah.
The Davis Polk corporate team included partners Alan F. Denenberg and Stephen A. Byeff and associates Savannah J. Dowling and Matthew Franklin. The intellectual property team included partner Frank Azzopardi and associate Adrian Rabin. Counsel Liang Zhang and associates Alanna Phillips and Fred Fu provided tax advice. Members of the Davis Polk team are based in the Northern California and New York offices.